lynparza
astrazeneca ab - olaparib - neoplazme jajnika - antineoplastična sredstva - jajnika cancerlynparza prikazan kao monoterapija za:podržava liječenje odraslih bolesnika s поздними (figo faze iii i iv) u genima brca1/2-mutirani (зародышевой linije i/ili somatskih) brzorezni epitela jajnika, masterbatch cijevi ili primarni перитонеальный rak, koji u odgovor (potpuno ili djelomično) nakon završetka prve linije na bazi platine kemoterapije. maintenance treatment of adult patients with platinum sensitive relapsed high grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) to platinum based chemotherapy. lynparza in combination with bevacizumab is indicated for the:maintenance treatment of adult patients with advanced (figo stages iii and iv) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy in combination with bevacizumab and whose cancer is associated with homologous recombination deficiency (hrd) positive status defined by either a brca1/2 mutation and/or genomic instability (see section 5. breast cancerlynparza is indicated as:monotherapy or in combination with endocrine therapy for the adjuvant treatment of adult patients with germline brca1/2-mutations who have her2-negative, high risk early breast cancer previously treated with neoadjuvant or adjuvant chemotherapy (see sections 4. 2 i 5. monotherapy for the treatment of adult patients with germline brca1/2-mutations, who have her2 negative locally advanced or metastatic breast cancer. pacijenti moraju prethodno bile tretirane s антрациклина i таксана u (neo)adjuvantne ili метастатический, ako pacijenti nisu prikladni za tih postupaka (vidi odjeljak 5. pacijenti s receptore hormona (h)-pozitivnog raka dojke treba također razvili ili nakon pre-hormonska terapija, ili se smatraju neprikladnim za endokrine terapije. adenocarcinoma of the pancreaslynparza is indicated as:monotherapy for the maintenance treatment of adult patients with germline brca1/2-mutations who have metastatic adenocarcinoma of the pancreas and have not progressed after a minimum of 16 weeks of platinum treatment within a first-line chemotherapy regimen. prostate cancerlynparza is indicated as:monotherapy for the treatment of adult patients with metastatic castration-resistant prostate cancer (mcrpc) and brca1/2-mutations (germline and/or somatic) who have progressed following prior therapy that included a new hormonal agent. in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with mcrpc in whom chemotherapy is not clinically indicated (see section 5.
xermelo
serb sas - telotristat etiprat - carcinoid tumor; neuroendocrine tumors - ostali prehrambeni proizvodi i proizvodi metabolizma - xermelo je indiciran za liječenje dijareje karcinoidnih sindroma u kombinaciji s terapijom somatostatinskog analoga (ssa) u odraslih koji su nedovoljno kontrolirani ssa terapijom.
sunitinib pliva 12,5 mg tvrde kapsule
pliva hrvatska d.o.o., prilaz baruna filipovića 25, zagreb, hrvatska - сунитиниб - kapsula, tvrda - 12,5 mg - urbroj: jedna kapsula sadrži 12,5 mg sunitiniba
sunitinib pliva 25 mg tvrde kapsule
pliva hrvatska d.o.o., prilaz baruna filipovića 25, zagreb, hrvatska - сунитиниб - kapsula, tvrda - 25 mg - urbroj: jedna kapsula sadrži 25 mg sunitiniba
sunitinib pliva 37,5 mg tvrde kapsule
pliva hrvatska d.o.o., prilaz baruna filipovića 25, zagreb, hrvatska - сунитиниб - kapsula, tvrda - 37,5 mg - urbroj: jedna kapsula sadrži 37,5 mg sunitiniba
sunitinib pliva 50 mg tvrde kapsule
pliva hrvatska d.o.o., prilaz baruna filipovića 25, zagreb, hrvatska - сунитиниб - kapsula, tvrda - 50 mg - urbroj: jedna kapsula sadrži 50 mg sunitiniba
zesuva 12,5 mg tvrde kapsule
zentiva k.s., u kabelovny 130, dolni mecholupy, prag 10, Češka - сунитиниб - kapsula, tvrda - 12,5 mg - urbroj: jedna kapsula sadrži 12,5 mg sunitiniba
zesuva 25 mg tvrde kapsule
zentiva k.s., u kabelovny 130, dolni mecholupy, prag 10, Češka - сунитиниб - kapsula, tvrda - 25 mg - urbroj: jedna kapsula sadrži 25 mg sunitiniba
zesuva 37,5 mg tvrde kapsule
zentiva k.s., u kabelovny 130, dolni mecholupy, prag 10, Češka - сунитиниб - kapsula, tvrda - 37,5 mg - urbroj: jedna kapsula sadrži 37,5 mg sunitiniba
zesuva 50 mg tvrde kapsule
zentiva k.s., u kabelovny 130, dolni mecholupy, prag 10, Češka - сунитиниб - kapsula, tvrda - 50 mg - urbroj: jedna kapsula sadrži 50 mg sunitiniba